Eli Lilly and Company

Daniel Anthony Briere

Avinash Muppidi

Daniel Christopher Lopes

John Lee

Hongchang Qu

Lili Guo

Samantha Grace Lyons Keyser

Milata Mary Abraham

PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.

Protein tyrosine-tyrosine analogs and methods of using the same

The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

Long acting amylin receptor agonists and uses thereof

Growing community of inventors

Morgantown, IN, United States of America

Daniel Anthony Briere